{"id":"W4408979201","doi":"10.1016/s1556-0864(25)00220-5","title":"25P: Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase III POSEIDON extended China cohort","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Durvalumab; Tremelimumab; Oncology; Chemotherapy; Cohort; Internal medicine; Phase (matter); China; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001925083,0.000839144,0.001228325,0.0002537704,0.000277082,0.0008085588,0.0007223998,0.0003927044,0.002386408],"category_scores_gemma":[0.0008953916,0.000281275,0.001761009,0.0004932563,0.0006435074,0.0007888855,0.0005613303,0.001346309,0.0005058226],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001680708,"about_ca_system_score_gemma":0.002383407,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005258796,"about_ca_topic_score_gemma":0.01343642,"domain_scores_codex":[0.9995655,0.0001333213,0.00001801516,0.0001030143,0.00008274747,0.00009744141],"domain_scores_gemma":[0.9994994,0.00006379846,0.0001195759,0.00006291534,0.00003339121,0.0002208123],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5793481,0.006699419,0.1102998,0.001195156,0.009866463,0.0003656804,0.0003039931,0.005839955,0.01719716,0.000731694,0.02203037,0.2461222],"study_design_scores_gemma":[0.3274956,0.1295156,0.4757248,0.0003008313,0.01502434,0.001113028,0.0003988086,0.005435157,0.007408818,0.001456199,0.03595254,0.0001743213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853799,0.003788247,0.0004594586,0.0006195048,0.0001276174,0.0003675157,0.007128138,0.00005386459,0.002075726],"genre_scores_gemma":[0.9696483,0.004196075,0.001150314,0.001310925,0.0001471967,0.0007045738,0.01914994,0.00006206949,0.003630709],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005258796,"threshold_uncertainty_score":0.0121944,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03606020486824633,"score_gpt":0.4327114401567048,"score_spread":0.3966512352884585,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}